Avantor (NYSE:AVTR) Stock Rating Reaffirmed by Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Avantor (NYSE:AVTR) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $31.00 target price on the stock.

AVTR has been the subject of a number of other reports. Barclays decreased their target price on Avantor from $28.00 to $25.00 and set an overweight rating for the company in a research note on Friday, June 28th. Evercore ISI lowered their target price on Avantor from $28.00 to $27.00 and set an outperform rating for the company in a research note on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Avantor from $23.00 to $25.00 and gave the company a hold rating in a research note on Thursday, April 18th. Stifel Nicolaus increased their price objective on shares of Avantor from $27.00 to $28.00 and gave the stock a buy rating in a research report on Monday. Finally, Citigroup lowered shares of Avantor from a buy rating to a neutral rating and reduced their target price for the stock from $30.00 to $23.00 in a research note on Wednesday, July 10th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $27.21.

Avantor Trading Down 1.0 %

Shares of NYSE AVTR opened at $26.49 on Monday. Avantor has a twelve month low of $16.63 and a twelve month high of $28.00. The stock has a market cap of $18.01 billion, a price-to-earnings ratio of 67.92, a P/E/G ratio of 2.82 and a beta of 1.32. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89. The company’s fifty day moving average is $22.56 and its 200-day moving average is $23.76.

Insiders Place Their Bets

In other Avantor news, insider Christophe Couturier 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Avantor

Hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc increased its position in Avantor by 2,003.6% during the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after buying an additional 1,102 shares during the last quarter. Fifth Third Bancorp raised its stake in Avantor by 125.3% in the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after acquiring an additional 694 shares during the period. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in Avantor by 565.5% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock valued at $30,000 after purchasing an additional 1,131 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares during the last quarter. Finally, Gladius Capital Management LP acquired a new position in shares of Avantor in the fourth quarter valued at approximately $42,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.